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Purpose: The purpose of this study was to determine the cost-effectiveness of carotid 
endarterectomy for treating asymptomatic patients with >-60% internal carotid stenosis, 
based on outcomes reported in the Asymptomatic Carotid Atherosclerosis Study 
(ACAS). 
Methods: A cost-effectiveness analysis was performed using a Markov decision model in 
which the probabilities for base-case analysis (average age, 67 years; 66% male; perioper- 
ative stroke plus death rate, 2.3%; ipsilateral stroke rate during medical management, 
2.3% per year) were based on ACAS. The model assumed that patients who had TIAs or 
minor strokes during medical management crossed over to surgical treatment, and used 
the NASCET data to model the outcome of these now-symptomatic patients. Average 
cost of surgery ($8500), major stroke ($34,000 plus $18,000 per year), and other costs 
were based on local cost determinations plus a review of the published literature. 
Cost-effectiveness was calculated as the incremental cost of surgery per quality-adjusted 
life year (QALY) saved when compared with medical treatment, discounting at 5% per 
year. Sensitivity analysis was performed to determine the impact of key variables on 
cost-effectiveness. 
Results: In the base-case analysis, surgical treatment improved quality-adjusted life 
expectancy from 7.87 to 8.12 QALYs, at an incremental lifetime cost of $2041. This 
yielded an incremental cost-effectiveness ratio of $8,000 per QALY saved by surgical 
compared with medical treatment. The high cost of care after major stroke during 
medical management largely offset the initial cost of endarterectomy in the surgical 
group. Furthermore, 26% of medically managed patients eventually underwent endarter- 
ectomy because of symptom development, which also decreased the cost differential. 
Sensitivity analysis demonstrated that the relative cost of surgical treatment increased 
substantially with increasing age, increasing perioperative stroke rate, and decreasing 
stroke rate during medical management. 
Conclusion: For the typical asymptomatic patient in ACAS with >-60% carotid stenosis, 
our results indicate hat carotid endarterectomy is cost-effective when compared with 
other commonly accepted health care practices. Surgery does not appear cost-effective in 
very elderly patients, in settings where the operative stroke risk is high, or in patients with 
very low stroke risk without surgery. (J Vasc Surg 1997;25:298-311.) 
Carotid artery atherosclerosis an important 
cause of  stroke when significant stenosis exists in the 
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carotid bulb. 1 Natural history studies have demon- 
strated a 2% to 5% annual ipsilateral stroke risk for 
internal carotid artery (ICA) stenoses --50% diame- 
ter reduction, increasing with stenosis everity.l-8 Ac- 
cordingly, prophylactic carotid endarterectomy 
(CEA) has been recommended to prevent future 
stroke in asymptomatic patients with severe carotid 
stenosis. 1 Recently, the Asymptomatic Carotid Ath- 
erosclerosis Study (ACAS) was performed to deter- 
mine whether the addition of CEA to aggressive 
medical management would reduce the incidence of 
stroke in patients with asymptomatic 60% to 99% 
ICA stenosis. 2 The results of this randomized, pro- 
spective, multicenter t ial demonstrated that the an- 
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Fig. 1. Markov decision analysis model (simplified) comparing medical management versus 
surgical treatment ofasymptomatic carotid stenosis. (*Surgery only if no previous stroke) 
nual ipsilateral stroke rate was reduced from 2.3% per 
year under medical management to 1% per year by 
CEA (p = 0.004). 
Although the relative reduction in stroke risk of 
54% by CEA in the ACAS appeared significant, he 
absolute 5-year stroke reduction from 11% to 5.1% 
seemed less substantial. In fact, the ACAS authors 
noted that 19 CEAs would have to be performed to 
prevent one stroke in 5 years. 2 As noted in the ac- 
companying editorial, it was not clear whether the 
observed benefits of carotid surgery warranted the 
associated expense. 9 To address this question, we 
developed a decision analysis model to compare 
medical management versus CEA plus medical man- 
agcment for patients with asymptomatic ->60% ICA 
stenosis. This model allowed us to determine the 
clinical circumstances in which CEA would improve 
quality-adjusted life expectancy and to calculate the 
cost-effectiveness of CEA in these settings. 
METHODS 
Decision model. We developed a decision anal- 
ysis model to reflect he possible clinical outcomes of 
a hypothetical cohort of asymptomatic patients with 
->60% ICA stenosis who were initially selected for 
either medical management or surgical treatment 
(medical management plus CEA, Fig. 1). Analogous 
to the ACAS strategy, we assumed that patients in 
the medical group would receive aspirin and risk 
factor reduction, but would not undergo CEA as 
long as they remained asymptomatic. 2 Unlike ACAS, 
but to more accurately reflect current clinical prac- 
tice, we assumed that patients in the medical group 
would undergo CEA if they experienced a transient 
ischemic attack (TIA) or a minor stroke. We used a 
computerized Markov decision analytic model (De- 
cision Maker 7.05 software, S.G. Pauker, 1995), an 
iterative process in which patients from a large hypo- 
thetical cohort make transitions between health 
states over t ime) ° Probabilities are assigned to all 
possible events and each health state is assigned a
cost and a quality adjustment score from 0 (death) to 
1 (alive without stroke), as described below. By mod- 
eling each hypothetical cohort until all patients are 
dead, a Markov model then calculates the quality- 
adjusted life expectancy and the lifetime costs for 
each strategy. The incremental cost-effectiveness ra- 
tio of surgical treatment is then calculated as the 
incremental cost per quality-adjusted life year 
(QALY) saved by surgical compared with medical 
management. (Note that a decrease in the cost-effec- 
tiveness ratio [doUars/QALYs] translates into im- 
proved "cost-effectiveness.') By varying the value of 
different variables (e.g., perioperative stroke rate) 
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Table I. Probabilities, utilities, and costs used in decision model 
Base-case Range 
analysis tested Reference* 
Patient demographics 
Age (years) 67 50-90 2, [Estimate] 
Gender (% male) 66 0-100 2, [Estimate] 
Medical treatment outcome 
TIA rate (%/yr) 2.1 1.8-2.8 2, [4,12] 
Ipsilateral stroke rate (%/yr) 2.3 0.7-6.8 2, [5,11] 
Major stroke (% of all strokes) 50 43-76 2, [ 17,20 ] 
Surgical treatment outcome 
Asymptomatic patient 
Stroke or death (30 day, %) 1.7 0-4.2 ACAS, [4,13] 
Ipsilateral stroke rate (%/yr) 0.6 0-2 ACAS, [ 1,4] 
Reoperation rate (%/yr) 0.6 0-2.5 14, [15,16] 
Symptomatic patient 
Stroke or death (30 day, %) 5.8 2.9-7.5 17, [18,19] 
Arteriography 
Stroke or death (%) 1.1 0-6.5 20 
Utilization (%) 50 0-100 2, [Estimate] 
Major stroke outcome 
Mortality (30 day, %) 15 3-20 22, [23,25] 
Excess mortality (%/yr) 2.7 1.6-6.6 23, [22,26] 
Quality-adjustment factors 
Alive, no stroke 1 
Major stroke 0.39 0.2-0.8 27, [28,29] 
Recurrent major stroke 0.12 0.i-0.5 27, [Estimate] 
Death 0 
Disutilities 
Minor stroke (weeks) 12 0-52 Estimate 
Arteriogram (weeks) .05 0-1 Estimate 
Carotid endarterectomy (weeks) 2 0-6 Estimate 
Costs 
Major stroke 
First year ($) 34,000 21,000-48,000 21,32, [32] 
Annual ($/yr) 18,000 9,500-32,000 Estimate, [32,33] 
Minor stroke 9,000 6,000-14,000 21,32, [32] 
Arteriography ($) 1,600 1,000-3,500 Estimate, [30,31] 
Endarterectomy ($) 8,500 7,500-i1,600 Estimate, [30,31] 
*First reference applies to base-case estimate. References in brackets apply to range estimate for sensitivity 
analysis. 
over their plausible range, the model can determine 
the impact of  this variable alone on cost-effectiveness 
(sensitivity analysis). We performed one-way sensitiv- 
ity analysis for the variables in Table I, and report the 
results o f  those that changed surgical cost-effective- 
ness by more than $10,000/QALY.  
Probabil i t ies. For our base-case analysis, we 
used demographic data (mean age, 67 years; 66% 
male) and results from ACAS. 2 We determined the 
plausible range for these variables based on a litera- 
ture review, with emphasis on population-based 
studies when possible. We restricted our analysis to 
cerebral events ipsilateral to the asymptomatic ca- 
rotid stenosis. For the base-case analysis, we applied 
the ACAS observation for ipsilateral stroke rate un- 
der medical management o f 2.3% per year. 2 As a low 
estimate o f  annual ipsilateral stroke rate for sensitivity 
analysis, we used 0.75% per year, based on a review of  
patients with ->50% ICA stenosis contralateral to a 
previous CEA. n As a high estimate for ipsilateral 
stroke rate, we used 6.8% per year, derived from a 
group of  patients with 50% to 79% ICA stenosis who 
progressed to ->80% stenosis during follow-up s (Ta- 
ble I). We also applied an annual ipsilateral hemi- 
spheric T IA  rate o f  2.1% per year to the base-case 
analysis, 2 and tested this variable over its reported 
clinical range 4,12 (Table I). 
For asymptomatic patients who underwent CEA 
(surgical group), we estimated the 30-day periopera- 
tive stroke or death rate to be 2.3%, based on ACAS 
results. 2 We separated the portion of  this risk that 
results from surgery alone (1.7%) for more precise 
modeling when testing the impact o f  arteriography 
(see below). In sensitivity analysis, we used a low 
estimate of  perioperative stroke and death rate o f  0% 
based on a single institution series. 13 As the upper 
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estimate, we used a 4.2% perioperative stroke or 
death rate, based on a high-risk group of male pa- 
tients from the Veteran's Administration Coopera- 
tive Study.  4 Again using ACAS, we estimated the 
long-term ipsilateral stroke rate at 0.6% per year after 
surgery in asymptomatic patients. 2 We tested the 
impact of this variable over the range of 0% to 2% per 
year, based on relevant clinical experience ~,4 (Table 
I). After CEA in asymptomatic patients, we also 
modeled the possibility of recurrent stenosis requir- 
ing reoperative CEA. For our base-case analysis, we 
estimated this rate at 0.6% per year, based on long- 
term follow-up of asymptomatic patients in large 
surgical series after CEA 14-16 (Table I). 
For patients in the medical group who developed 
TIAs or minor strokes and then underwent CEA, we 
used outcomes probabilities from the North Ameri- 
can Symptomatic Carotid Endarterectomy Trial 
(NASCET) for our base-case analysis. 17 Thus we 
estimated the 30-day stroke or death rate after CEA 
in symptomatic patients to be 5.8%. As a low estimate 
for sensitivity analysis, we used a 2.9% perioperative 
stroke or death rate, based on the Cleveland Vascular 
Registry) s As a high estimate, we used the 7.5% 
perioperative stroke or death rate reported in the 
European Carotid Surgery Trial. 19 After surgery in 
symptomatic patients, we assumed a late ipsilateral 
stroke rate equivalent to asymptomatic patients. 
For preoperative arteriographic evaluation of 
asymptomatic patients, we assigned an ipsilateral 
stroke or death risk of 1.1% and tested this over the 
range of 0% to 6.5%, based on a large meta-analysis. 2° 
As in ACAS, we assumed that 50% of the base-case 
cohort underwent preoperative arteriographic evalu- 
ation, yielding a total operative plus arteriographic 
stroke or death rate of 2.3%. We also tested the 
impact of arteriographic complications by varying 
the proportion of patients who undergo preoperative 
arteriographic evaluation. 
To estimate the expected survival rate for patients 
with carotid artery atherosclerosis, we added a con- 
stant excess mortality rate to the age- and sex- 
matched expected survival for the U.S. population. 
This was done to account for the additional cardiac 
mortality rate anticipated in this group. We applied 
an excess annual mortality rate of 0.5% per year based 
on the nonstroke mortality rate of all patients in- 
ACAS. 2 In addition to the excess mortality rate based 
on generalized atherosclerosis, we specifically mod- 
eled the reduction of survival rate based on major 
stroke in both the medical and surgical groups. For 
the base-case analysis, we estimated that 50% of all 
strokes were minor, with complete symptom resolu- 
tion within 3 months, based ,on definitions used in 
ACAS and NASCET. 2,17 We tested this variable over 
its reported range 17,21 (Table I). We estimated the 
30-day mortality rate of major stroke to be 15%, 
based on population-based studies. 22-2~ To address 
the known increased late mortality rate for survivors 
of major stroke, we added an excess annual mortality 
rate of 2.7% per year to the expected base-case mor- 
tality rate. 22,23,26 We accounted for the increased 
probability of a recurrent stroke following a first 
major stroke based on data from the Framingham 
study, which demonstrated a threefold increased risk 
of ipsilateral stroke. 22 We assumed that medical and 
surgical patients had comparable ong-term survival, 
except for potential differences in stroke-related mor- 
tality and perioperative surgical mortality rates, 
which we specifically modeled. 
Quality adjustment. Long-term quality of life 
adjustment for stroke was based on a published util- 
ity assessment in elderly patients (0.39, first major 
stroke; 0.12, recurrent stroke).27 In sensitivity analy- 
sis, we tested the quality-adjustment for major stroke 
over the range of 0.2 to 0.8, based on other literature 
estimates. 28,29 These quality-adjustment factors are 
multiplied by actual life expectancy to obtain quality- 
adjusted life expectancy. For example, if a patient 
survived 5 years after a major stroke, the quality- 
adjusted life expectancy would be 0.39 × 5 years, or 
1.95 QALYs. Quality adjustment for temporary con- 
ditions was performed by subtracting "disutilities" 
from quality-adjusted life expectancy (Table I). We 
assumed that patients with minor stroke had com- 
plete symptom resolution by 3 months, and there- 
fore assigned a disutility of 0.25 years. Similarly, we 
applied a 2-week disutility to patients undergoing 
CEA, and a 3-day disutility to patients undergoing 
preoperative cerebral arteriographic s ans (Table I). 
Costs. We estimated the actual cost of CEA us- 
ing a standard cost accounting system. This is a 
fully-loaded cost model in which both fixed hospital 
overhead costs and variable costs specifically related 
to diagnosis related group 5 (DRG 5, CEA) are 
included. As an estimate of physician costs, we used 
the Medicare resource-based r lative-value system 
(RBRVS) for the appropriate CPT codes, including 
both surgical and anesthesia costs. For our base-case 
analysis, this resulted in a cost estimate for CEA of 
$8500. In sensitivity analysis, we tested the range of 
$7500 to $11,600, based on recent published cost 
estimates. 3°,3~ We estimated arteriographic osts 
based on selective two-vessel carotid arteriogram ob- 
tained in the outpatient setting with both cervical 
and intracranial views. Actual hospital costs were 
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Table II. Cost-effectiveness of selected 
medical practices 
Medical practice Cost/QALY* 
Treatment of mild-moderate hypertension 
compared with no treatment 
Propranolol 
Captopril 
Hemodialysis for end-stage renal disease 
Total hip replacement for severe 
osteoarthritis 
Coronary artery bypass compared to medical 
treatment of severe angina 
Left main disease 
Single-vessel disease 
Transplantation compared with medical 
treatment 
Heart 
Kddney 
Treatment of hyperlipidemia with 
cholestyramine 
Universal precautions for HIV prevention i  
health-care workers 
513,00035 
587,000 
553,00036 
$4,6003z 
57,000 a8 
551,000 
533,000 a9 
520,000 
$189,00040 
$770,00041 
*Cost estimates were adjusted to 1996 dollars using the consumer 
price index. 
derived as described above, and radiologists' cost 
were estimated from Medicare RBRVS reimburse- 
ment. For the base-case analysis we calculated this 
cost to be $1600 and tested this over a plausible 
range in sensitivity analysis, a°,31 
For the portion of patients who died during their 
hospitalization from stroke, we assigned a cost of 
$6800 based on our actual hospital cost estimate for 
DRG 14, plus Medicare RBRVS physician reim- 
bursement for daily visits by an internist, neurology 
consultation, and radiologic omputed tomographic 
scan interpretation. For patients who survived stroke, 
we estimated first year and subsequent stroke costs 
based on population-based studies in the recent liter- 
ature. For our base-case analysis, we estimated the 
cost of  minor stroke to be $9000, based on the 
average of two population-based tudies 21,32 and the 
observation that first-year stroke costs are 3.5 times 
higher for major than minor stroke. 21 In sensitivity 
analysis, we used the range of  estimates in these 
population-based studies of $6000 to $14,000. 32 
Because we assumed that all patients with minor 
stroke recovered by 3 months, there were no addi- 
tional recurrent costs assigned to this group beyond 
the first year. It was assumed that all patients who 
had and recovered from a minor stroke (and who had 
not had a previous major stroke) underwent CEA 
without an intercurrent event before surgery (Fig. 
1). For patients who survived major stroke, we esti- 
mated the first-year cost for our base-case analysis to 
be $34,000 based on the average of three popula- 
tion-based groups 21,32 and tested this value over the 
range of $21,000 to $48,000 based on the range of 
estimates in these reports. 21 Because of the costs of 
chronic nursing home care and home care for dis- 
abled patients after major stroke, we applied an an- 
nual cost after the first year of $18,000 to our base 
case analysis. This was derived as the average of 
recent published estimates and was tested over the 
range of these estimates, from $9,500 to 
$32,000. 32,33 These cost estimates for stroke in- 
cluded direct costs only. Indirect costs as a result of 
loss of wages or early retirement were not included. 
For patients who had a TIA during follow-up in the 
medical group, we did not assign additional specific 
costs, but rather assumed that these patients incurred 
only the cost of CEA at that time. 
All costs were normalized to 1996 dollars using 
the consumer price index for all urban consumers. A 
discount rate of 5% was used to adjust future costs 
and health benefits to their present value. The ratio- 
nale for discounting is that a dollar or QALY is worth 
more today than at some point in the future. We 
performed a sensitivity analysis to examine the effect 
of different discount rates, from 0% to 8% per year. 
RESULTS 
Base-case analysis 
In the base-case analysis (67-year-old patients), 
the average life expectancy (undiscounted) in the 
medical group was projected to be 11.6 year versus 
11.9 years in the surgical group. Quality-adjusted life 
expectancy (undiscounted) in the medical group was 
11.1 QALYs versus 11.6 QALYs in the surgical 
group. Discounting at 5% per year yielded a final 
projected quality-adjusted life expectancy of 7.87 
QALYs for medical and 8.12 QALYs for surgical 
treatment, a ditikrence of 0.25 QALYs (3 months) in 
favor of surgical treatment for the base-case cohort. 
The predicted lifetime (discounted) cost was 
$12,407 for medical and $14,448 for surgical treat- 
ment, a difference of $2041 in favor of medical treat- 
ment. Thus the incremental cost-effectiveness ratio 
for surgical treatment in the base-case analysis was 
$8004 per QALY saved compared with medical 
treatment ($2,041 / 0.25 QALYs). This cost-effec- 
tiveness ratio compares favorably with other com- 
monly accepted medical practices (Table II). 
As expected, the majority of costs in the medical 
group were associated with late stroke, while most 
costs in the surgical group were associated with end- 
arterectomy (Fig. 2). In the medical group, 79% of 
costs were attributed to the initial and subsequent 
annual care of patients with major stroke, and 15% of 
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Fig. 2. Lifetime cost estimates (di counted at 5%) for 
medical and surgical treatment of 67-year-old patients. 
Medical patients experienced total costs that were 52000 
less than surgical patients, heavily allocated to care after 
major stroke. Costs for surgical patients were predomi- 
nantly influenced by initial procedural costs. 
costs were associated with subsequent endarterec- 
tomy for patients who became symptomatic. In con- 
trast, 67% of total costs in the surgical group were 
associated with endarterectomy, with 31% of costs 
attributable to care for major stroke in this cohort. 
In our base-case analysis, 26% of medically man- 
aged patients eventually experienced symptoms that 
led to CEA, due to the projected annual rate of TIAs 
(2.1% per year) and minor stroke (1.1% per year, 
based on ACAS). This proportion significantly de- 
creased with age, being 32% for 60-year-old patients, 
but only 14% for 80-year-old patients, reflecting 
their reduced life expectancy. I n medically managed 
patients who later required CEA for symptoms, this 
was performed after a median of 5.5 years (mean, 7.9 
years). 
The impact of major stroke was substantial in our 
base-case analysis. Without discounting, the pro- 
jected life expectancy after major stroke was 7.9 
QALYs, at a lifetime cost of $192,000. With 5% 
discounting, the projected life expectancy after major 
stroke was only 5.8 QALYs, at a projected cost of 
$151,000. Of these costs, 30% were associatcd with 
care during the first year after major stroke, while 
70% were associated with chronic care of that portion 
of patients who remained isabled after major stroke 
(Fig. 2). In the base-case analysis, 12% of medical 
patients experienced a major stroke during their life- 
time, including 1% who experienced stroke after later 
surgery for TIA or minor stroke. In the surgical 
group, only 5% of patients experienced major stroke 
during their lifetime, a risk reduction of 58% com- 
pared with medical management (and comparable 
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Fig. 3. Cost-effectiveness of urgical treatment compared 
with medical management as a function of age in the 
base-case analysis. Shading indicates three categories of 
cost-effectiveness: le s than $20,000/QALY, clearly cost- 
effective; 520,000 to 5100,000, intermediate cost-effec- 
tiveness; greater han 5100,000, not cost-effective. By 
these definitions, surgical tre tment is "cost-effective" until 
at ieast age 72, and perhaps age 79. 
with the 53% stroke risk reduction observed in 
ACAS). 2 
Sensitivity analysis 
Age. The variable that most significantly influ- 
enced cost-effectiveness in our model was patient age 
at initial presentation (Fig. 3). For patients younger 
than 71 years, the cost of surgical treatment was less 
than $20,000/QALY, and for patients younger than 
60 years, surgical treatment was dominant (both 
more effective and less expensive). Above age 70, the 
cost of surgical treatment increased rapidly, exceed- 
ing $100,000/QALY at age 79. This exponential 
increase in cost-effectiveness with increasing age can 
be attributed to decreased life expectancy, with re- 
duced opportunity for stroke prevention and recov- 
ery of initial surgical costs in older, asymptomatic 
patients. 
Stroke rate during medical management. The 
second variable with a major influencc on cost-effec- 
tiveness was the ipsilateral stroke rate observed dur- 
ing medical management. At the low end of 
predicted stroke risk (0.7% per year), medical man- 
agement was both more effective and less expensive 
for all age groups. At the upper end of this range 
(6.8% per year reported for asymptomatic patients 
whose stenoses progressed to >80% during follow- 
upS), surgical treatment was dominant for all age 
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Fig. 4. Cost-effectiveness of surgical treatment as a func- 
tion of ipsilateral stroke rate during medical management 
for three different age groups. For young patients (age 55), 
surgery is cost-effective even at low annual stroke risk (1.5% 
per year). For older patients (age 75), surgery is cost- 
effective only if medical stroke risk is high (>2.5% per 
year). The broken line at 2.3% annual stroke riskindicates 
the base-case assumption based on ACAS. 
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Fig. 5. Cost-effectiveness of surgical treatment as a func- 
tion ofperioperative stroke or death rate for three different 
age groups. For young patients, surgery is cost-effective 
even at higher operative vent rates. For older patients, 
however, perioperative event rate must be much lower for 
surgical treatment to be cost-effective. The broken line a t  
2.3% indicates the base-case assumption for perioperative 
event rate based on ACAS. 
groups. The influence ofipsilateral stroke risk during 
medical management over the range of 1% to 3% per 
year is shown in Fig. 4 for different age groups. 
Perioperative event rate. Perioperative stroke 
or death rate associated with CEA also had a signifi- 
cant influence on the cost-effectiveness of surgical 
treatment, although not as substantial n effect as age 
or stroke rate during medical management. In the 
base-case analysis, the cost of surgical treatment was 
only $630/QALY if the perioperative event rate (in- 
cluding arteriography) was 0.5%, increasing to 
$14,450/QALY if the perioperative event rate was 
4.2%. For patients younger than age 65, the cost of 
surgical treatment was <$20,000/QALY with peri- 
operative vent rates as high as 6% (Fig. 5). Such a 
high perioperative stroke rate xceeds the recom- 
mended thresholds for performing CEA in asymp- 
tomatic patients 1 and would be expected to result in 
an early 3% major stroke rate. However, this is offset 
by the cumulative 12% stroke rate that occurs during 
medical management, which makes surgical treat- 
ment cost-effective at higher perioperative risk in 
such young patients. For patients older than 75 years 
of age, however, the cost of surgical treatment ex- 
ceeds $20,000/QALY at a periopcrative event rate 
of only 2%, reinforcing the important influence of 
age on the choice of medical or surgical treatment 
(Fig. 5). 
Costs. Of  the costs examined in this model, only 
the annual cost of major stroke and the cost of CEA 
had a significant effect on cost-effectiveness when 
examined by sensitivity analysis over their expected 
range (Table I). For the base-case patient, the cost of 
surgical treatment increased from $8,000/QALY to 
$13,000/QALY if the annual cost of major stroke 
care was at the low end of this range estimate 
($9,500 per year). At the upper estimate for this 
variable ($32,000 per year), surgical treatment was 
dominant for the base-case patient. For CEA costs, 
the cost of surgical treatment was $4,800/QALY at 
the low estimate of cost ($7500), increasing to 
$18,000/QALY at the upper end of this cost esti- 
mate ($11,600 ). To simultaneously estimate the po- 
tential impact of all cost estimates in our model, we 
developed an upper and lower estimate for the possi- 
ble range of cost-effectiveness of surgical treatment. 
As a high cost estimate (worst case for surgery), we 
used the lowest cost estimates for stroke care and the 
highest cost estimates for CEA and arteriographic 
scans. As a low cost estimate (best case for surgery), 
we used the highest cost estimates for stroke care and 
the lowest cost estimates for surgery and arterio- 
graphic scans. These results for the base-case analysis 
are shown in Fig. 6 as a function of age. For a 
70-year-old patient, the cost of surgical treatment 
increases from $15,200/QALY (base-case assump- 
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tions) to $43,400/QALY at the high cost estimate. 
At the low cost estimate, the cost of surgical treat- 
ment remains <$20,000/QALY even up to age 80. 
Other  variables. Several other variables influ- 
ence the cost-effectiveness of surgical treatment in 
our model. As expected, the discount rate for future 
benefits and costs had a substantial effect because of 
the different times at which surgical and medical 
patients experience CEA and major stoke. In the 
base-case analysis, surgical treatment was dominant 
at a discount rate less than 2.2%, while the cost 
increased to $20,400/QALY at a discount rate as 
high as 8%. The proportion of strokes that are major 
also influenced cost-effectiveness. In the base-case 
analysis, the cost of  surgical treatment increased from 
$1,500/QALY if 70% of all strokes were major to 
$12,700/QALY if only 40% of all strokes were ma- 
jor. 
Two other variables had a borderline influence on 
cost-effectiveness. In the base-case analysis, the cost 
of surgical treatment increased from $3,600/QALY 
if no patients underwent arteriographic scans to 
$13,300/QALY if all patients underwent arterio- 
graphic scans. As expected, the stroke or death rate 
associated with arteriography also affected the cost of 
surgical treatment. I f 50% of patients underwent ar- 
teriographic scans (base-case assumption), the cost of 
surgical treatment increased from $6,000/QALY at 
a 0% stroke or death rate to $25,000/QALY if the 
arteriographic stroke or death rate was as high as 
6.5%. 2o These calculations concerning the impact of 
arteriographic scans do not assign an incremental 
benefit o arteriography (see discussion). The effect 
of  gender in our analysis was only specifically mod- 
eled by an effect on life expectancy and did not 
include a differential benefit of CEA, which has been 
suggested but not proven. 2 If all the patients in our 
base-case analysis had been women, the cost of sur- 
gical treatment would have been $2,100/QALY. 
This cost would increase to $11,600/QALY if all 
patients had been men, reflecting the reduced sur- 
vival rate of  male patients and comparable with the 
effect of increasing age in the base-case analysis. The 
other variables tudied by sensitivity analysis in our 
model (Table I) did not have a significant effect on 
the cost-effectiveness of urgical treatment. 
DISCUSSION 
After years of debate, the NASCET and ACAS 
results have provided significant evidence for the 
benefit of CEA in both symptomatic and asymptom- 
atic patients with >60% to 70% ICA stenosis. 2,17 
These studies demonstrated a similar reduction of 
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Fig. 6. Extreme stimates (shaded range) for cost-effec- 
tiveness of surgical treatment asa function of age, based on 
varying cost for surgical and medical care. High cost esti- 
mate uses the lowest cost for stroke care and the highest 
cost for surgery. Low cost estimate uses the highest cost for 
stroke care and the lowest cost for surgery (Table I). 
ipsilateral stroke risk, 65% in NASCET and 53% in 
ACAS. However, the absolute reduction of stroke 
risk was 17% after 2 years in NASCET compared with 
only 6% after 5 years in ACAS. This difference reflects 
the greater likelihood of stroke during medical man- 
agement of symptomatic patients (13% per year in 
NASCET) compared with asymptomatic patients 
(2.3% per year in ACAS). 2,17 Thus although CEA for 
symptomatic patients with significant ICA stenosis 
has received widespread support following 
NASCET, the translation of ACAS results into clini- 
cal practice has been more variable. This largely re- 
flects the question of whether the performance of 19 
CEAs to prevent one stroke in asymptomatic patients 
can be justified given the expense of the surgical 
procedure. The answer to this question is not 
straightforward, however, because of the high cost of 
care after major stroke and the portion ofasymptom- 
atic patients with ->60% ICA stenosis who later de- 
velop TIAs or minor stroke and then incur the cost of 
CEA. To analyze these opposing effects we con- 
structed a Markov decision analysis model based on 
the ACAS results. For the average-aged ACAS pa- 
tient, our results demonstrate hat CEA has an incre- 
mental cost-effectiveness ratio of $8,000/QALY 
when added to aggressive medical management. 
There is considerable debate conccrning the appro- 
priate cost-effectiveness threshold beyond which spe- 
cific procedures or treatments are too "expensive" 
and should not receive hcalth care resources. How- 
ever, technologies that cost less than $20,000/ 
QALY are almost universally accepted as being an 
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appropriate xpenditure of societal resources. 34Fur- 
thermore, many technologies that cost between 
$20,000 and $100,000/QALY are commonly pro- 
vided, and even some very expensive technologies 
have gained widespread acceptance (Table II). 34-41 
By these standards, it appears that CEA is both ap- 
propriate and cost-effective for many patients with 
asymptomatic ->60% ICA stenosis. 
The most important factor that should influence 
asymptomatic patient selection for CEA is age, be- 
cause older patients with limited life expectancy have 
less opportunity to benefit from stroke risk reduction 
after CEA. Our analysis uggests that CEA is cost- 
effective for asymptomatic patients up to approxi- 
mately age 75 if they have an average life expectancy 
for this group of patients. For patients 75 to 80 years 
of age, the cost-effectiveness of CEA increases to the 
upper limit of the acceptable range, such that only 
patients with particularly good life expectancy would 
be appropriate candidates for surgery. For asymp- 
tomatic patients older than 80 years, it is unlikely 
that CEA can be cost-effective unless the expected 
stroke risk during medical management is much 
higher than normal. This impact of age is especially 
important because carotid atherosclerosis is known 
to increase as a function of age. In screening studies 
of asymptomatic men, the incidence of ICA stenosis 
->50% increased from 4% at age 60 to 64 years to 11% 
at older than 75 years. 42 Thus most patients with 
severe carotid stenosis are older than the average age 
of 67 years in the ACAS, where enrollment was 
restricted to patients 40 to 79 years of age. 2 This 
observation indicates that most asymptomatic ca- 
rotid stenoses will be detected in patients who are the 
least likely to experience benefit from prophylactic 
CEA, which underscores the importance of careful 
patient selection. 
Predicting stroke risk during medical manage- 
ment of patients with asymptomatic carotid disease is 
important for appropriate decision making because 
of the demonstrated impact of this variable on the 
cost-effectiveness of urgical treatment. Several stud- 
ies have reported quite similar estimates of stroke risk 
during medical management. In the ACAS, for pa- 
tients of average age 67 years who had 60% to 99% 
ICA stenoses, the observed ipsilateral stroke rate dur- 
ing medical management was 2.3% per year. 2 In the 
Veterans Administration Cooperative Study, the ob- 
served ipsilateral stroke rate during medical fol- 
low-up was 2.4% per year, for male patients of aver- 
age age 65 years with 50% to 99% ICA stenoses. 4 In 
the CASANOVA trial, the stroke rate was 3.8% per 
year in medically managed patients of average age 64 
years who had 50% to 90% carotid bulb stenoses. 7 In 
asymptomatic patients evaluated by Doppler ultra- 
sound, Norris et al. 6 observed an annual stroke rate 
of 2.5% per year during medical management of 
patients with >75% ICA stenosis. Finally, Mansour 
et al. 5 observed an annual ipsilateral stroke rate of 
2.3% during follow-up of asymptomatic patients with 
initially 50% to 79% ICA stenosis,  Based on these 
reports, our estimate of 2.3% per year for ipsilateral 
stroke risk during medical management seems appro- 
priate. 
Further research to more accurately predict the 
stroke risk of specific carotid lesions would be valu- 
able for more precise decision making in individual 
patients. At present, there is convincing evidence 
that progression of ICA stenosis during follow-up 
substantially increases troke risk. In the asymptom- 
atic patients with 50% to 79% ICA stenosis who were 
observed by Monsour et al., the stroke rate was only 
0.23% per year if the stenosis did not progress,  
However, if stenosis progression to >80% occurred, 
the stroke rate increased to 6.8% per year. Other 
investigators have also demonstrated a detrimental 
effect of ICA stenosis progression in asymptomatic 
patients in terms of subsequent TIAs, stroke, or ca- 
rotid occlusion rate. 43 Carotid ulceration and plaque 
composition also appear to predict stroke risk during 
medical treatment. ~ Although carotid ulceration is 
difficult o detect, initial reports uggest that echolu- 
cent plaque, detectable by duplex ultrasound, signif- 
icantly increases the likelihood of future symptoms. 44
An important observation i our analysis is that a 
substantial number of asymptomatic patients with 
->60% ICA stenosis will eventually have ipsilateral 
TIA or minor stroke and undergo CEA for symp- 
tomatic disease at that time. For patients as young as 
60 years of age, fully one third are expected to de- 
velop such symptoms during their lifetime, based on 
the ACAS risk estimates of 2.1% per year for ipsilat- 
eral TIA and 1.1% per year for ipsilateral minor 
stroke. This effect decreases with age, but has an 
under-appreciated influence on the ultimate cost of 
medical management. 
The cost estimates used in our model are impre- 
cise but reflect he current status of this information 
in the medical literature. The cost accounting system 
in our hospital that was applied to CEA and arteriog- 
raphy is a relatively precise and rigorous method of 
accounting for total direct and indirect hospital 
costs. Although there is less agreement about an 
ideal definition for physician costs, the Medicare 
RBRVS is the most widely accepted current proxy 
available to estimate these expenses. Thus, we are 
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relatively confident of our cost estimates for carotid 
surgery and arteriography and found a comparable 
range estimate in the literature. 3°,31 The costs of 
stroke are much more variable in the literature and 
reflect both differences in patient mix and differences 
in the types of costs induded in these analyses. 27-30,4s 47 
We selected population-based studies thatattempted 
to incorporate not only institutional costs associated 
with acute hospitalization, rehabilitation, and chronic 
nursing home care, but also home care costs associ- 
ated with permanently disabled stroke patients. 2a,32 
We did not, however, include indirect costs of stroke 
in our model, such as those caused by loss of employ- 
ment, which have been estimated to increase total 
stroke cost by 32%. 32 
Our base-case stimate for major stroke cost of 
$34,000 for the first year and $18,000 for subse- 
quent years, derived from population-based studies, 
also agrees with our own institutional estimate of 
these costs. Based on a review of 187 consecutive 
stroke patients (DRG 14) discharged from our hos- 
pital during 1995, we found that 54% were dis- 
charged to home, 28% to a rehabilitation facility, and 
18% to chronic nursing care. Under the assumption 
that 50% of all strokes were minor (based on ACAS), 
we estimated the discharge status of major stroke 
patients to be 20% to home, 40% to rehabilitation, 
and 40% to chronic nursing care. This coincides with 
an estimate by Mauthe et al.4s for patients with major 
stroke (functional independence measure <90) of 
I8% to home, 41% to rehabilitation and 41% to 
nursing care. By 3 months, we estimated that 76% of 
all stroke patients would be living at home, in close 
agreement with three population-based stimates of 
65%, 77%, and 77%.21,26,32 We estimated that 18% 
of all stroke patients (36% of major stroke patients) 
would ultimatcly require chronic nursing home care, 
identical to a recent estimate for stroke care in the 
Netherlands. 49Based on these estimates for patients 
discharged from our institution, we derived cost es- 
timates from our cost accounting system for DRG 
14; for physician daily visits and neurology consulta- 
tion from Medicare RBRVS; for rehabilitation from 
national average reimbursement after major strokeS°; 
and for nursing home care based on national average 
reimbursement, sa These results yielded our indepen- 
dent estimate of $31,000 as the first-year cost for 
major stroke. For subsequent years, average nursing 
home cost alone was $8400 per year, an estimate that 
does not include any cost for home care, which has 
been estimated at 120% of chronic institutional 
costs? 2 This led to our own estimate of an annual 
cost of $18,500 per year after major stroke. These 
estimates are in close agreement with our base-case 
literature-derived stimates for the cost of major 
stroke ($34,000 initial plus $18,000 per year). To 
test the impact of different cost estimates, we have 
provided an extreme high and low range for the 
cost-effectiveness of surgical treatment (Fig. 6). 
More accurate determinations of the precise cost of 
stroke care would increase the reliability of any cost- 
effectiveness model. 
For our base-case analysis wc assumed that 50% 
of patients underwent a carotid arteriographic s an 
before surgical treatment, based on the experience in
ACAS. We have analyzed the impact ofarteriography 
cost, but have not allocated a specific benefit o this 
diagnostic method. Thus carotid arteriography is
simply an excess cost and risk in our model that does 
not improve benefit. This assumption is debatable, 
but a recent analysis by Kent et al? ° suggests that 
carotid arteriography is not cost-effective when com- 
pared with duplex ultrasound in the evaluation of 
patients with symptomatic carotid disease. Further- 
more, a decision analysis tudy by the same authors 
suggests that arteriography does not add diagnostic 
value to duplex ultrasound in asymptomatic pa- 
tients, s2 Although excellent results have been re- 
ported from centers that perform a high volume of 
carotid arteriography, the 1.2% stroke rate observed 
in ACAS 2 and the 1% stroke rate derived from a large 
meta-analysis 2° suggests that this diagnostic method 
may have greater a morbidity rate than generally 
assumed. For these reasons we did not attach a sig- 
nificant benefit o carotid arteriography in our analy- 
sis. However, an accurate quantitation of the degree 
of ICA stenosis is critical to the initial decision mak- 
ing for patients with asymptomatic disease. Thus 
surgeons who make these decisions without carotid 
arteriographic scans must have high confidence in 
the accuracy of their duplex ultrasound examina- 
tions, based on frequent correlation with arteriogra- 
play. 
Several assumptions made in our model deserve 
comment. First, we assumed the perspective of the 
ACAS, namely, the appropriate management of pa- 
tients after a significant ICA stenosis has been identi- 
fied. These results cannot be extrapolated to justify 
the screening costs of detecting these stenoses, how- 
ever. This "question eeds to be explored separately 
and was beyond the scope of our current analysis. 
However, because carotid stcnoses are now being 
identified with duplex ultrasound in patients with 
asymptomatic bruits or multiple risk factors for ath- 
erosclerosis, appropriate decisions must be made for 
these patients, which was the purpose of our current 
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study. Second, we have assumed that the risks calcu- 
lated on the basis o f  ACAS continued in a linear 
fashion beyond 5 years. We believe that this is rea- 
sonable given the linear appearance o f  the ACAS life 
table analyses. 2 However, it is likely that carotid disease 
progression will occur ha medical patients during long- 
term follow-up, and likely increase the later risk of  
stroke during medical management. Thus our assump- 
tion of  a linear stroke risk during medical management 
may bias our model against surgical treatment. 
Cost-effectiveness analyses cannot substitute for 
clinical judgement when recommending appropriate 
treatment for individual patients. However, these 
analyses are ideally suited to highlight the trade-offs 
between costs and benefits o f  CEA in asymptomatic 
patients. Furthermore, they serve to identify impor- 
tant key variables, such as age, which have a substan- 
tial influence on the cost-effectiveness of this deci- 
sion. Our  study should not be interpreted as an 
indiscriminate recommendation for performing CEA 
in asymptomatic patients, for several reasons. First, 
our model is based on outstanding surgical results 
achieved by experienced surgeons in a highly moni- 
tored multicenter trial. Thus physicians who recom- 
mend CEA for asymptomatic patients must be confi- 
dent of  their own results or the results o f  their 
surgeons. Second, life expectancy has an extremely 
important influence on cost-effectiveness and is diffi- 
cult to precisely calculate in individual patients. Al- 
though we have assumed an excess mortality rate as a 
result o f  cardiac disease in our model, there are some 
patients with asymptomatic arotid disease who 
clearly have more than the expected excess mortality 
rate. In these patients, surgical treatment is less likely 
to be cost-effective. Finally, although the results of  
ACAS significantly increased our knowledge con- 
cerning the outcome of  medical and surgical treat- 
ment of  asymptomatic patients, a number o f  ques- 
tions remain unanswered. These include the impact 
on stenosis severity within the range of  60% to 99% 
and possible differential gender effects, which require 
more study. 2Our results suggest, however, that CEA 
is cost-effective in asymptomatic patients 75 years o f  
age or less with >-60% ICA stenosis, when compared 
with other commonly accepted medical practices. 
REFERENCES 
1. Moore WS, Barnett HIM, Beebe HG, Bernstein EF, Brener 
BI, Brott T, et al. Guidelines for carotid endarterectomy: a 
multidisciplinary consensus statement from the AdHoc Com- 
'mittee, American Heart Association. Str ke I995;26:188- 
201. 
2. Executive Committee for the Asymptomatic Carotid Athero- 
sclerosis Study. Endarterectomy for asymptomatic carotid ar- 
tery stenosis, lAMA 1995;273:1421-8. 
3. European Carotid Surgery Trialists' Collaborative Group. 
Risk of stroke in the distribution of an asymptomatic carotid 
artery. Lancet 1995;345:209-12. 
4. Hobson RW II, Weiss DG, Fields WS, Goldstone J, Moore 
WS, Towne JB, etal. Efficacy of carotid endarterectomy for 
asymptomatic carotid stenosis. N Engl J Med 1993;328: 
221-7. 
5. Mansour MA, Mattos MA, Faught WE, Hodgson KJ, Bark- 
meier LD, Ramsey DE, Sumner DS. The natural history of 
moderate (50% to 79%) internal carotid artery stenosis in 
symptomatic, nonhemispheric, and asymptomatic patients, l 
Vasc Surg 1995;21:346-58. 
6. Norris JW, Zhu CZ, Bomstein NM, Chambers BR. Vascular 
risks of asymptomatic carotid stenosis. Stroke 1991;22:1485- 
90. 
7. The CASANOVA Study Group. Carotid surgery versus med- 
ical therapy in asymptomatic carotid stenosis. Stroke 1991;22: 
1229-35. 
8. Ellis MR, Franks Pl, Cuming R, Powell IT, Greenhalgh RM. 
Prevalence, progression and natural history of as mptomatic 
carotid stenosis: is there a place for carotid endarterectomy? 
Eur J Vasc Surg 1992;6:172-7. 
9. Mayberg MR, Winn HR. Endarterectomy forasymptomatic 
carotid artery stenosis: re olving the controversy. JAMA 
1995;273:1459-61. 
10. Beck JR, Pauker SG. The Markov process in medical progno- 
sis. Med Decis Malting 1983;3:419-58. 
11. Durward Q l, Ferguson GG, Barr HWK. The natural history 
of asymptomatic carotid bifurcation plaques. Stroke 1982; 13: 
459-64. 
12. Shanik GD, Moore DJ, Leahy A, Grouden MC, Colgan MP. 
Asymptomatic carotid s enosis: a benign lesion? Eur J Vasc 
Surg 1992;6:10-5. 
13. Riles TS, Fisher FS, Lamparello PI, Giangola G, Gibstein L, 
Mintzer R, et al. Immediate and long-term results of carotid 
endarterectomy forasymptomatic high-grade stenosis. A n 
Vasc Surg 1994;8:144-9. 
14. Freischlag IA, Hanna D, Moore WS. Improved prognosis for 
asymptomatic carotid stenosis with prophylactic carotid end- 
arterectomy. Stroke 1992;23:479-82. 
15. Healy DA, Clowes AW, Zierler RE, Nicholls SC, Bergelin 
RO, Primozich IF, et al. Immediate and long-term results of 
carotid endarterectomy. Stroke 1989;20:1138-42. 
16. Anderson RI, Hobson RW, II, Padberg FT, Pecoraro JP, 
DeGoote RD, Jamil Z, et al. Carotid endarterectomy for 
asymptomatic carotid stenosis: a ten-year experience with 120 
patients in a fellowship training program. Ann Vasc Surg 
1991;5:111-5. 
17. North American Symptomatic Carotid Endarterectomy Trial 
Collaborators. Beneficial effect of carotid endarterectomy in 
symptomatic patients with high-grade carotid stenosis. 
N Engl l Med 1991;325:445-53. 
18. Rubin JR, Pitluk HC, King TA, Hutton M, Kieger EF, Plecha 
FR, Hertzer NR. Carotid endarterectomy in a metropolitan 
community: the early results after 8535 operations. I Vasc 
Surg 1988;7:256-60. 
19. European Carotid Surgery Trialists' Collaborative Group. 
MRC European Carotid Surgery Trial: interim results for 
symptomatic patients with severe (70-99%) or with mild (0- 
29%) carotid stenosis. Lancet 1991;337:1235-43. 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 2 Cronenwett  et al. 309 
20. Hankey GL, Warlow CP, Sellar RJ. Cerebral angiographic 
risk in mild cerebrovascular disease. Stroke 1990;21:209-22. 
21. Thorngren M, Westling B. Utilization of health care re- 
sources after stroke: a population-based study of 258 hospi- 
talized cases followed uring the first year. Acta Neurol Scand 
1991;84:303-10. 
22. Sacco RL, WolfPA, Kannel WB, McNamara PM. Survival and 
recurrence following stroke: the Framingham study. Stroke 
1982;13:290-5. 
23. Min Lai S, Alter M, Friday G, Sobel E. Prognosis for survival 
after an initial stroke. Stroke 1995;26:2011-5. 
24. Dennis MS, Burn JPS, Sandercock PAG, Bamford JM, Wade 
DT, Warlow CP. Long-term survival after first-ever stroke: 
the Oxfordshire Community Stroke Project. Stroke 1993;24: 
796-800. 
25. Bonita R, Broad JB, Beaglehole R. Changes in stroke inci- 
dence and case-fatality in Auckland, New Zealand, 1081-91. 
Lancet 1993;342:1470-3. 
26. Persson U, Silverberg R, Lindgren B, Norrving B, Jadback G, 
Johansson B, et al. Direct costs of stroke for a Swedish 
population. Int J Technol Assess Health Care 1990;6:125- 
37. 
27. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effec- 
tiveness of warfarin and aspirin for prophylaxis of stroke in 
patients with nonvalvular atrial fibrillation. JAMA 1995;274: 
1839-45. 
28. Matchar DB, Pauker SG. Endarterectomy in carotid artery 
disease: a decision analysis. JAMA 1987;258:793-8. 
29. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effective- 
ness of ticlopidine in preventing stroke in high-risk patients. 
Stroke 1994;25:1149-56. 
30. Kent KC, Kuntz KM, Patel MR, Kim D, Klufas RA, Whitte- 
more AD, et al. Perioperative imaging strategies for carotid 
endarterectomy. JAMA 1995;274:888-93. 
31. Lavenson GS, Jr, Sharma D. Cost savings of carotid endarter- 
ectomy: value of one surgeon in one year. Perspect Vasc Surg 
1994;7:1-20. 
32. Ter6nt A, Mark6 LA, Asplund K, Norrving B, Jonsson E, 
Wester PO. Costs of stroke in Sweden: anational perspective. 
Stroke 1994;25:2363-9. 
33. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost- 
effectiveness model ofthrombolytic therapy for acute myocar- 
dial infarction. J Gen Intern Med 1995;10:321-30. 
34. Lanpacis A, Feeny D, Detsky AS, Tugwell PX. How attractive 
does a new technology have to be to warrant adoption and 
utilization? Tentative guidelines for using clinical and eco- 
nomic evaluations. Can Med Assoc J 1992;146:473-81. 
35. Edelson JT, Weinstein MC, Tosteson ANA, Williams L, Lee 
TH, Goldman L. Long-term cost-effectiveness of various ini- 
tial mouotherapies for mild to moderate hypertension. JAMA 
1990;263:408-13. 
36, Stange PV, Sumner AT. Predicting treatment costs and life 
expectancy for end-stage renal disease. N Engl J Med 1978; 
298:372-8. 
37. Chang RW, Pellissier JM, Hazen GB. A cost-effectiveness 
analysis of total hip arthroplasty of osteoarthritis of the hip. 
JAMA 1996;275:858-65. 
38. Weinstein MC, Stason WB. Cost-ett~ctiveness of coronary 
artery bypass surgery. Circulation 1982;66:III56-66. 
39. Evans RW. Cost-effectiveness analysis of transplantation. Surg 
Clin North Am 1986;66:603-16. 
40. Weinstein MC, Stason WB. Cost-effectiveness of interven- 
tions to prevent or treat coronary heart disease. Annu Rev 
Public Health 1985;6:41-63. 
41. Stock SR, Gafni A, Bloch RF. Universal precautions to pre- 
vent HIV transmission to health care workers: an economic 
analysis. Can Med Assoc J 1990;142:937-46. 
42. O'Leary DH, Polak JF, Kromnal RA, Kittner SJ, Bond MG, 
Wolfson SK Jr, et al. Distribution and correlates of sono- 
graphically detected carotid artery disease in the cardiovascu- 
lar health study. Stroke 1992;23:1752-60. 
43, Roederer GO, Langlois YE, Jager ICA, Primozich JF, Beach 
KW, Phillips DJ, et al, The natural history of carotid arterial 
disease in asymptomatic patients withcervical bruits. Stroke 
1984;15:605-13. 
44. Geroulakos G, Domjan J, Nicolaides A, Stevens J, Labropou- 
los N, Ramaswami G, et al. Ultrasonic arotid artery plaque 
structure and the risk of cerebral infarction on computed 
tomography. J Vasc Surg 1994;20:263-6. 
45. Smurawska LT, Alexandrov AV, Bladin CF, Norris JW. Cost 
of acute stroke care in Toronto, Canada. Stroke 1994;25: 
1628-31. 
46. Dobkin B. The economic impact of stroke. Neurology 1995; 
45(suppl 1):$6-9. 
47. Kellett J, Clarke J. Comparison of "accelerated" tissue plas- 
minogen activator with streptokinase for treatment of sus- 
pected myocardial infarction. Med Dec Making 1995;15: 
297-310. 
48. Mauthe RW, Haaf DC, Hayn P, Krall JM. Predicting dis- 
charge destination of stroke patients u ing a mathematical 
model based on six items from the functional independence 
measure. Arch Phys Med Rehabil 1996;77:10-3. 
49. Bergman L, van de Meulen JHP, Limburg M, Habbema JDF. 
Costs of medical care after first-ever stroke in the Nether- 
lands. Stroke 1995;26:1830-6. 
50. McGinnis GE, Osberg JS, Seward ML, Campion EW, Branch 
LG, DeJong G. Total charges for inpatient medical rehabili- 
tation. Health Care Financing Rev 1988;9(4):31-40. 
51. Van Nostrand JF, Furner SE, Suzman R, eds. Health data on 
older Americans: United States, 1992. National Center for 
Health Statistics. Vital Health Stat 1993;3(27):221. 
52. Kuntz KM, Skillman JJ, Whittemore AD, Kent KC. Carotid 
endarterectomy in asymptomatic patients--Is contrast an- 
giography necessary? A morbidity analysis. J Vasc Surg 1995; 
22:706-16. 
Submitted June 14, 1996; accepted Sep. 10, 1996. 
JOURNAL OF VASCULAR SURGERY 
31'0 Cronenwett et al. February 1997 
DISCUSSION 
Dr. K. Craig Kent (Boston, Mass.). Dr. Cronenwett 
and his colleagues at Dartmouth ave once again come to 
our rescue with an excellent, well-designed, and informa- 
tive analysis of a very controversial issue. We have learned 
today that for the average patient studied in ACAS, the 
cost per quality-adjusted life year saved for performing 
carotid endarterectomy is $8000. This cost is approxi- 
mately equivalent to that for performing coronary artery 
bypass grafting for left main disease, an intervention that 
few would dispute as efficacious. 
Do the results of this analysis mean that vascular sur- 
geons have been vindicated? Should all asymptomatic pa- 
tients who have a >60% carotid stenosis be scheduled for 
carotid endarterectomy? Dr. Cronenwett appropriately 
warns that we should not use the results of his analysis as a 
license to indiscriminately perform carotid endarterec- 
tomy. In sensitivity analysis, he has demonstrated that the 
cost-effectiveness of carotid endarterectomy rapidly dimin- 
ishes in older patients. In fact, the cost rises to a value of 
greater than $100,000 per quality-adjusted life year saved 
when endarterectomy is considered in patients who are 79 
years of age or older. This value is clearly higher than what 
society usually pays for interventions. Thus it does not 
appear to be cost-effective to perform carotid endarterec- 
tomy in asymptomatic patients who have reached their late 
seventies and eighties. 
In conjunction with my colleagues at the Harvard 
School of Public Health, we performed a similar analysis 
• that we presented at least year's American Heart Associa- 
tion meetings. We found that performing carotid endarter- 
ectomy in the typical ACAS patient resulted in a cost per 
quality-adjusted life year saved of approximately $50,000. 
Thus our findings were not quite as favorable as those from 
the Dartmouth group. In comparing these two analyses, 
the differences were as follows. 
We assumed an added mortality rate in these patients 
of approximately 5% per year because of coexisting myocar- 
dial disease. We derived this number from a natural history 
study of asymptomatic patients by Chambers and Norris. 
This variable was also considered in the Dartmouth study, 
but they have introduced an added mortality rate for these 
patients as a result of myocardial disease of only 0.5% per 
year, a tenth of the number that we used. A more signifi- 
cant mortality rate in these patients that results from other 
causes (i.e., myocardial infarction) would shorten their 
life-expectancy and thus reduce the benefit of endarterec- 
tomy. 
This leads to my first question. Because it has long 
been recognized that carotid disease is a marker for myo- 
cardial arteriosclerosis, doyou not think the additional risk 
of death from coronary artery disease in these patients is 
greater than 0.5% per year? Did you perform sensitivity 
analyses with this variable to evaluate what effect an in- 
crease in this number might have had on your base-case 
analysis? 
Also, when calculating the rate of stroke in these pa- 
tients, you used only ipsilateral stroke, despite the fact that 
many of these patients have cerebrovascular events from 
contralateral disease. These contralateral events also pro- 
duce complications and death that should be taken into 
consideration when determining outcome and costs for 
these patients. Would inclusion of contralateral strokes in 
your analysis have significantly changed your base concl3J- 
sion? 
Your estimate cost of carotid endarterectomy, for the 
actual procedure itself, was approximately $8000. This is 
low compared with the estimates of others, and a low 
procedure cost obviously enhances the efficacy of any 
intervention. What were the mechanisms that you used 
at Dartmouth that allowed carotid endarterectomy to be 
so inexpensive? I hope you have not cut your surgeons' 
fees! 
Dr. Cronenwett has convincingly shown us that ca- 
rotid endarterectomy is cost-effective in young asymptom- 
atic patients whose life-expectancy is great. However, there 
are still many unanswered questions. Are there subgroups 
of older patients who will also benefit from endarterectomy 
(possibly those with 90% stenoses, ulcers, progressive ste- 
noses, or those with complex plaque)? I would admonish 
that it is still necessary for vascular surgeons to continue 
their attempts to define subsets of patients who might 
achieve a benefit from carotid endarterectomy that is 
greater than that found in ACAS. 
I would like to thank the Society and Dr. Cronenwett 
for the opportunity to review this very excellent study that 
assuredly will increase our understanding of carotid artery 
disease and contribute to our management of these pa- 
tients. 
Dr. Jack L. Cronenwett. Thanks very much, Dr. 
Kent, for your comments. Your previous experience with 
this type of modeling has obviously allowed you to dissect 
out some of the details in our model. 
Your first question relates to how much excess mortal- 
ity risk a patient with asymptomatic carotid stenosis has. 
We based our assignment of 0.5% per year excess mortality 
rate on the results in ACAS. This estimate also agreed with 
that of an independent s udy that we performed in survi- 
vors of coronary bypass who had carotid disease. The 
reason that this estimate differs from the Norris study is 
that that study included death from stroke in their excess 
mortality calculation, whereas we sp cifically modeled 
death from stroke as an independent cause of later death, 
so I suspect hat our overall results perhaps are not that 
much different. 
You are correct in pointing out, however, that age, as 
an estimate of life-expectancy, is very important for appro- 
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pilate decision making. Patients who will have a predict- 
ably shorter life expectancy will not enjoy the benefit of 
prophylactic endarterectomy. 
We did not include instances of contralateral stroke in 
our model because we did not expect ipsilateral surgery to 
prevent hese. Furthermore, we made the implicit assump- 
tion that the contralateral stroke rate would be the same in 
the medical nd surgical groups, so I do not believe that 
that would affect our results. 
We have not changed the surgical fees that Medicare 
allows us at Dartmouth. We have, as others have reported, 
decreased length of stay, use of the intensive care unit, and 
other factors to reduce the actual cost of caring for these 
patients. And we believe that our cost estimates are accu- 
rate, but we did test them over a fairly wide range. 
Dr. Robert  B. Rutherford (Denver, Colo.). In view 
of the significant differences between men and women in 
the ACAS outcome data, did you perform separate projec- 
tions for gender in this analysis? And if so, how would the 
results of that affect your decision tree? 
Dr. Cronenwett. As you know, the statistical signifi- 
cance of those observations in ACAS was not proven, and 
so we didn't try to overstep those conclusions and specifi- 
cally model gender differences in stroke rate. However, we 
can simulate these differences by varying both the medical 
stroke rate and the perioperative stroke risk, which are 
potentially different in men and women. This can be done 
from the details of our manuscript, and hopefully draw the 
appropriate conclusions. However, until better data are 
available on the exact impact of gender, we thought it was 
premature to try to model that impact a  this time. 
Dr. Robert  W. Hobson I I  (Newark, N.J.). In design- 
ing future clinical trials that compare carotid endarterec- 
tomy and angioplasty, would you recommend this method 
in the analysis of data? And have you made any preliminary 
judgments with regard to angioplasty with this modeling? 
Finally, have these data influenced your current prac- 
tice? In elderly patients, are you adjusting the recom- 
mended threshold egree of stenosis of ACAS from a 60% 
diameter-reducing stenosis upward to 80% before consid- 
ering carotid endarterectomy in asymptomatic patients? 
And have your cost analyses influenced practice on your 
service? 
Dr. Cronenwett. I think your comment points out 
the need for better estimates of the anticipated stroke risk 
during medical management alone. There are some tanta- 
lizing variables that need more investigation, such as the 
characteristics of plaque by duplex scan and the progres- 
sion rate of stenoses, that might differentiate patients who 
have a relatively higher or lower stroke risk, and that risk 
could be factored into our decisions. To directly answer 
your questions, we are certainly being more conservative in 
recommending carotid endarterectomy for asymptomatic 
elderly patients. Particularly for patients more than 80 
years of age, I believe that they need to have a progressing 
stenosis, a more severe stenosis, or an echolucent stenosis 
for us to recommend endarterectomy if they are asymp- 
tomatic. 
We have not specifically modeled the potential cost of 
performing balloon a gioplasty or stent placement, but 
obviously the cost of this procedure would have to be 
substantially ower than the $8500 cost of surgery to have a 
significant impact on the outcome. 
Dr. John J. Ricotta (Buffalo, N.Y.). One of the things 
that I did not catch in your model is whether you changed 
the medical risk of stroke from 2.3% and determined what 
effect hat change in risk had? The thing that people forget 
about ACAS is this rate of 2.3% per year in the medical arm 
is about half of what every other retrospective or natural 
history study has shown for high-grade stenosis, and it may 
suggest that identifying these patients and following them 
with best medical management, which is what was done in 
ACAS, has reduced the stroke rate. I wonder whether 
changing that stroke rate to the 4% or 5% that Jack Norris 
reported, or that Gene Strandness has reported in his 
natural history studies, would have any effect? 
Second, what do you think this result says about our 
need to identify these patients with disease in terms of 
either history or screening, because it appears that people 
who are identified with target lesions, whether they are in 
the carotid or coronary situation, seem to do a lot better 
than people in whom target lesions are not identified. 
Dr. Cronenwett. I believe that there is actually rela- 
tively good convergence on this estimate of approximately 
2.3% per year stroke risk during medical management, 
because itwas the same in the VA cooperative trial, and it is 
very similar in the European results. But I think you are 
correct that there are subgroups of patients that have 
higher stroke risk; and the Norris study, which looked at 
patients with even more severe stenosis, is a good example 
of that factor. We did demonstrate a significant impact of 
medical stroke risk in our sensitivity analysis. 
We did not consider the question of whether screening 
for asymptomatic stenosis is cost-effective in this particular 
study. I believe that one would have to focus on a sub- 
group of patients, such as those who have atherosclerotic 
peripheral occlusive disease, which the Oregon group has 
shown to have a higher incidence of carotid disease, to 
make that type of screening cost-effective. 
Dr. Alex N. Simpson (South Plainfield, N.J.). I just 
have one question. Concerning arteriography, I saw the 
utilization slide that you had, did you consider factoring in 
not using arteriography at all, including the cost and the 
morbidity that it entails, considering the accuracy of non- 
invasive methods and the unlikely possibility that informa- 
tion obtained from arteriography may modify surgery? 
Dr. Cronenwett. We did analyze that question and 
the details are in our manuscript. As you might expect, if 
you assign no incremental value to arteriography, then it 
simply adds cost and morbidity to the model. Thus per- 
forming no arteriograms would further increase the cost- 
effectiveness of surgical treatment in this model. 
